Single Molecule Counting (SMC®) Technology 單分子生物標誌物檢測技術

高靈敏度 = 降低背景值 + 提升訊號強度

SMC®技術在遵循與傳統ELISA技術相似的工作流程同時，提供了最佳的免疫分析性能，如下所示。

通過結合獨特的測定洗脫步驟（elution）和強大的計數功能，SMC®技術比傳統的免疫測定技術具有更高的訊號雜訊比。

因此，SMC®技術可在一個完整系統上以低和高表達水平提供增強的定量。

SMC® 單分子生物標誌物檢測術原理

我有興趣

SMC®免疫原性開發套組

SMC®發表文獻

SMC®免疫分析套組

	LLOQ (pg/mL)1	Median Endogenous (pg/mL)2	Species3	Sample Type4	Sample volume ( μ L)	MTO or STOCK	Cat. No.
Akt1 (Ser473)	0.98	NA	H, M, R	L	varies 8	MTO	03-0100-01
Akt1 (total)	7.8	NA	H, M, R	L	varies 8	MTO	03-0099-01
Amyloid beta 1-40 6,7	5.86	Normal CSF: 1366; P: 152	H, M, R	C, P	5, 25	STOCK	03-0145-00
Amyloid beta 1-42 6,7	0.98	Normal CSF: 192; P: 15	H, M, R	C, P	5, 25	STOCK	03-0146-00
BDNF 6,7	0.04	P: 783; S: 410; CSF: 0.13 H		C, P, S	100, 1, 1	STOCK	03-0171-00
cTnI 6,7	0.69	P: 3.04; S: 3.02	H, Cy, R, C, GP	P, S	100	STOCK	03-0154-00
G-CSF	0.08	17	H	P	10	MTO	03-0047-00
GLP-1 (active)	0.4	3.46	H, M, R, C	P	100	MTO	03-0024-03
GLP-1 (total)	0.39	17.8	H, M, R, C	P	20	MTO	03-0025-06
Glucagon 6,7	0.78	44	H, M, R	P	10	STOCK	03-0153-00
GM-CSF	0.02	0.2	H	P	100	MTO	03-0067-00
IFN-α2 6,7	0.031	P: 0.08; S: 0.08	H	P, S	100	STOCK	03-0186-00
IFN- β 1 [new]	0.15	P: 0.35; S: 0.64	H	P, S	50	STOCK	03-0191-00
IFN-γ 6,7	0.03	P: 1.4; S: 1.4	H	P, S	25	STOCK	03-0181-00
IL-1α 6,7	0.12	P: 0.09; S: 0.10	H	P, S	100	STOCK	03-0167-00
IL-1β 6,7	0.2	P: 0.11; S: 0.12	H	P, S	100	STOCK	03-0160-00
IL-2	0.05	0.21	H	P, S	100	MTO	03-0051-00
IL-21	0.2	0.53	H	S	50	MTO	03-0014-07
IL-22 6,7	0.1	P: 1.51; S: 1.52	H	P, S	25	STOCK	03-0162-00
IL-23 6,7	0.1	P: 0.65; S: 0.46	H	P, S	100	STOCK	03-0157-00
IL-4 6,7	0.04	P: 0.18; S: 0.18	H	P, S	100	STOCK	03-0161-00
IL-5 6,7	0.04	P: 0.37; S:0.30	H	P, S	100	STOCK	03-0168-00
IL-6 6,7	0.08	P: 0.70; S: 0.69	H	P, S	75	STOCK	03-0155-00
IL-7	0.39	4.91	H	P, S	50	MTO	03-0094-00
IL-8 / CXCL8	0.24	3.6	H	P, S	50	MTO	03-0055-00
IL-10 6,7	0.1	P: 0.90; S: 0.89	H	P, S	100	STOCK	03-0176-00
IL-12p70 6,7	0.05	P: 0.29; S: 0.28	H	P, S	100	STOCK	03-0182-00
IL-13 6,7	0.04	P: 0.37; S: 0.33	H	P, S	100	STOCK	03-0156-00
IL-15	0.1	3.38	H	P, S	100	MTO	03-0058-00
IL-17A/F Heterodimer 6,7	1.17	P: 1.36; S: 3.20	H	P, S	50	STOCK	03-0177-00
IL-17A 6,7	0.07	P: 0.31; S: 0.30	H	P, S	50	STOCK	03-0159-00
IL-17F 6,7	0.2	P: 1.10; S: 1.18	H	P, S	50	STOCK	03-0164-00
IL-18 6,7 [new]	0.09	P: 138; S: 145	H	P, S	10	STOCK	03-0190-00
KIM-15	3.91	P: 65; S: 75; U: 147	H	P, S, U	25, 25, 5	MTO	03-0118-00
MCP-1 6,7	0.15	P: 682; S: 1021	H	P, S	1.56	STOCK	03-0187-00
Tau(Thr181) 6,7 [new]	0.94	P: 3.4; S: 2.0; C: 21	H	P, S, C	50, 100, 25	STOCK	03-0184-00
TNFα	0.4	38.6	M	S	25	MTO	03-0108-00
TNFα 6,7	0.2	P: 0.85; S: 0.78	H	P, S	100	STOCK	03-0163-00
TSLP 6,7	1.56	P: 5.04; S: 3.86	H	P, S	100	MTO	03-0172-00
VEGF-A 6,7	0.2	P: 48; S: 50	H	P, S	25	STOCK	03-0180-00
α-Synuclein(Ser129) 6,7 [new]	0.1	P: 2.74; S: 1.81; C: 0.64	H	P, S, C	20, 20, 50	STOCK	03-0188-00
SARS-CoV-2 RBD IgG [new]	NA9	NA9	H	P, S	2	STOCK	03-0193-00
UCHL1 [new]	2.6		H, M, R, Cy, C, F	P, S, C			03-0183-00
Total α-synuclein [new]	1.95		H, M, R, C, F	P, S, C	100		03-0196-00

LLOQ: Lowest point on standard curve with CV < 20% and accuracy within 20% of expected values.Median Endogenous: Minimum of 10 samples from individual donors assessed for ability to quantify baseline biomarker values.Optimized for first species type listed. Other listed species have been tested, but not optimized for peak performance.Key: H=Human; M=Mouse; R=Rat; GP=Guinea Pig; Cy=Cynomolgus Monkey; C=CanineOptimized for use in sample type(s) listed. Key: P=Plasma; S=Serum; L=Lysate; U=Urine; C=Cerebrospinal Fluid (CSF)Plate-based assay.Assay characteristic data is representative for both Erenna® and SMCxPRO™.New streamlined format kit. For list of changes refer to the new kits section.LLoQ: Lowest point on standard curve with CV < 20% and accuracy within 20% of expected values.Median Endogenous: Minimum of 10 samples from individual donors assessed for ability to quantify baseline biomarker values.Optimized for first species type listed. Other listed species have been tested, but not optimized for peak performance. Key: H=Human; M=Mouse; R=Rat; GP=Guinea Pig; Cy=Cynomolgus Monkey; C=Canine; F=FelineOptimized for use in sample type(s) listed. Key: P=Plasma; S=Serum; L=Lysate; U=Urine; C=Cerebrospinal Fluid (CSF)Plate-based assay.Assay characteristic data is representative for both ErennaR and SMCxPRO™.Streamlined format kit.Sample volume varies based on dilution factor selected by userQualitative assay

SMC®免疫原性開發套組

Description	Cat. No.
SMC® Immunogenicity Bead Based Assay Development	Kit 03-0175-00
384-well Bar-coded Aurora Plate (Case of 32 plates)	ABB2-10160A
384-well Aurora Plate (Case of 32 plates)	ABB2-00160A
One 384-well Aurora plate w/ 3 plate seals	02-1008-00

SMC® 技術應用亮點：免疫原性（Immunogenicity）

在藥物發現過程中，及早發現陰性免疫原性反應對於確保迅速識別潛在的免疫反應至關重要。

然後，當公司尋求開發對重大疾病具有改善的臨床療效和患者安全性的有效藥物時，可以做出明智的決定。

透過檢測抗藥物抗體（anti-drug antibodies, ADA），特別是IgG、IgM、IgE，可評估化合物的免疫原性。

FDA準則持續強調高靈敏度的重要性，因為這會導致早期發現對患者安全至關重要的原發性免疫反應。

使用SMC®技術與我們獨特的免疫原性測定開發套組相結合，研究人員可以開發一種簡單、易於設計和驗證的同種物種無關的橋接測定（bridging assay）。

SMC™免疫原性微珠的測定開發套件附有開發和驗證ADA測定所需的全部試劑。

全面的測定開發協議旨在指導和協助您進行整個過程。我們經驗豐富的應用科學家還可以幫助設計，驗證並培訓最終用戶以充分利用該平台。

CONTRACT RESEARCH ORGANIZATIONS USING SMC® TECHNOLOGY

ABL Lyon
Aptuit Verona Srl
BARC Global Central Laboratory
Beijing Evergreen Biotech Ltd
Covance Laboratories, Inc.
Charles River Laboratories
Eurofins BioAnalytics USA
Evotec AG
Firalis SAS
GX Sciences
IRBM
KCAS Bioanalytical Service
LGC Limited
LSI Medicine
Nuvisan GmbH

Pacific Biomarkers
PBL Assay Science
PDXen
PRA Health Sciences
Radix Biosolutions
SBH Diagnostics
Smithers Avanza
SNBL Japan
Swiss Bioquant
The Scientists Lab
Unimed
United-Power Pharma Tech co., Ltd
VINTAR Research Laboratories
WuxiApp Tech

我有興趣

SMC®免疫原性開發套組

SMC®完整清單下載